Company Overview
Revolution Medicines, Inc. operates as a clinical-stage precision oncology company focused on developing novel targeted therapies specifically designed for RAS-addicted cancers. The company's research and development pipeline is comprised of RAS(ON) inhibitors that bind to RAS variants, intended for use as monotherapy or in combination with other RAS(ON) inhibitors. This specialized focus places the firm within the broader Healthcare sector and the Biotechnology industry, a landscape characterized by high capital requirements for research and long development cycles before commercialization. As of the latest data, the company holds a market capitalization of $19.68B and employs 883 individuals, though specific annual revenue figures are not disclosed in the current reporting period. The substantial market cap relative to the absence of reported revenue indicates that the company's valuation is driven primarily by investor expectations of future potential and the clinical success of its pipeline rather than current commercial performance.
Financial Health
The company reports a net income of $-1,131,300,992 and an EBITDA of $-1,174,619,008, while specific revenue figures are not available in the current dataset. The significant gap between the reported net income and the near-zero revenue metrics reveals a cost structure dominated by heavy operational expenses, likely stemming from ongoing clinical trials and research and development activities rather than commercial sales. Free cash flow stands at $-523,279,008, which indicates that the company is currently consuming cash reserves to fund its operations and pipeline advancement rather than generating liquidity from its business activities. All three reported margins—gross margin, operating margin, and profit margin—are listed as 0.0%, reflecting a stage where costs associated with production and operations exceed or equal revenue, or where revenue is not yet recognized at scale. Despite these deficits, the company maintains a cash balance of $2.03B against total debt of $427.15M, resulting in a debt-to-equity ratio of 26.18. This balance sheet composition suggests a leveraged position relative to equity, yet the substantial cash hoard provides significant financial flexibility to sustain operations without immediate external financing. The current ratio is 7.14, which signals robust short-term liquidity as the company holds ample current assets to cover its short-term liabilities many times over. Furthermore, the return on equity is -58.1% and the return on assets is -30.1%, metrics that reveal management is currently generating negative returns on the capital deployed, a typical characteristic of clinical-stage biotechnology firms prior to product approval and revenue generation.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E stands at -14.74. The discrepancy between a non-existent trailing multiple and a negative forward multiple implies that the market is pricing in a trajectory where the company is expected to remain unprofitable in the near term, preventing the establishment of a traditional earnings-based valuation multiple. The price-to-book ratio is 11.99, indicating that the market values the company at a significant premium of nearly 12 times its net asset value, likely reflecting the high intangible value of its intellectual property and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio are listed as N/A, and the EV/EBITDA stands at -15.39, suggesting that traditional valuation frameworks are not applicable due to the lack of positive earnings or sales data. The stock has exhibited significant volatility, with a 52-week high of $124.49 and a 52-week low of $29.17. Without a specific current price provided in the facts, the range indicates a wide trading band where the asset has experienced substantial price discovery, moving from a low of approximately 23.4% of the high to the high itself. The beta value is 1.01, which means the stock's price volatility is roughly equivalent to that of the broader market, moving in tandem with general market fluctuations without showing extreme sensitivity or insulation.
Growth & Income
Specific revenue growth and earnings growth rates are listed as N/A, reflecting the company's status as a pre-revenue or early-revenue clinical-stage entity where historical growth comparisons are not yet established. In the absence of dividend data, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the company does not distribute cash to shareholders. Instead of paying dividends, the company retains all earnings—where negative earnings represent losses—and reinvests capital entirely into research, development, and clinical trial execution to advance its RAS(ON) inhibitor pipeline. The overall growth and income profile is defined by a focus on capital allocation toward scientific advancement rather than shareholder distribution, with growth metrics currently undefined until the company transitions to a profitable commercial stage.